Paper42416752
Targeting Mouse Double Minute 2 Homolog (MDM2) Oncogene in Breast Adenocarcinoma.
Niotis A and 7 others. Maedica (Bucur), 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Targeting Mouse Double Minute 2 Homolog (MDM2) Oncogene in Breast Adenocarcinoma. Papers, record 42416752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42416752
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References50
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 8048160 | The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger. | Trends Biochem Sci | 1994 | https://conductscience.org/library/papers/8048160 | PubMed |
| 2 | 41991605 | Mitochondrial translocation of MDM2 and TFAM reprograms metabolism in treatment-refractory cancers. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/41991605 | PubMed |
| 3 | 18834305 | Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. | Annu Rev Pharmacol Toxicol | 2009 | https://conductscience.org/library/papers/18834305 | PubMed |
| 4 | 41528114 | Cancer statistics, 2026. | CA Cancer J Clin | 2026 | https://conductscience.org/library/papers/41528114 | PubMed |
| 5 | 36987836 | Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS. | Future Oncol | 2023 | https://conductscience.org/library/papers/36987836 | PubMed |
| 6 | 28669344 | p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents. | Curr Cancer Drug Targets | 2018 | https://conductscience.org/library/papers/28669344 | PubMed |
| 7 | 38736923 | Management of an Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma of the Left Laterocervical Region: Report of a Rare Case. | Maedica (Bucur) | 2024 | https://conductscience.org/library/papers/38736923 | PubMed |
| 8 | 17116689 | Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. | Mol Cell Biol | 2007 | https://conductscience.org/library/papers/17116689 | PubMed |
| 9 | 16107876 | MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. | EMBO J | 2005 | https://conductscience.org/library/papers/16107876 | PubMed |
| 10 | 41657798 | Comprehensive profiling of somatic alterations and HRD characteristics in Chinese germline BRCA-mutated breast cancer patients. | Am J Cancer Res | 2026 | https://conductscience.org/library/papers/41657798 | PubMed |
| 11 | 2026149 | Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. | EMBO J | 1991 | https://conductscience.org/library/papers/2026149 | PubMed |
| 12 | 40191734 | Targeting MDM2-p53 interaction for breast cancer therapy. | Oncol Res | 2025 | https://conductscience.org/library/papers/40191734 | PubMed |
| 13 | 25396320 | Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. | J Med Chem | 2015 | https://conductscience.org/library/papers/25396320 | PubMed |
| 14 | 32300595 | Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet? | Front Cell Dev Biol | 2020 | https://conductscience.org/library/papers/32300595 | PubMed |
| 15 | 25739118 | Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation. | Oncotarget | 2015 | https://conductscience.org/library/papers/25739118 | PubMed |
| 16 | 17170710 | The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. | EMBO J | 2007 | https://conductscience.org/library/papers/17170710 | PubMed |
| 17 | 8529093 | Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. | Mol Med | 1995 | https://conductscience.org/library/papers/8529093 | PubMed |
| 18 | 9430646 | Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. | EMBO J | 1998 | https://conductscience.org/library/papers/9430646 | PubMed |
| 19 | 42056242 | Ginkgetin enhances the antitumor effect of Taxol on human breast cancer MCF-7 cells via ferroptosis mediated by the MDM2-p53-YAP1 axis. | Sci Rep | 2026 | https://conductscience.org/library/papers/42056242 | PubMed |
| 20 | 21376230 | Hallmarks of cancer: the next generation. | Cell | 2011 | https://conductscience.org/library/papers/21376230 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42416752
GET https://conductscience.org/api/papers/v1/42416752/references?page=2